Advances in Biologic and Monoclonal Antibody Therapies for the Management of Psoriasis: A Comprehensive Overview

Abstract

Background: Psoriasis is a chronic inflammatory skin disorder affecting approximately 3% of the global population, significantly impacting quality of life and incurring substantial healthcare costs. Recent advancements in biological therapies, particularly monoclonal antibodies targeting specific cytokines, have transformed the treatment landscape for moderate to severe psoriasis.

Methods: This review encompasses a thorough analysis of current literature on biologic therapies and monoclonal antibodies for psoriasis management, focusing on their mechanisms of action, efficacy, and safety profiles. The review includes data from clinical trials, meta-analyses, and real-world studies published up to 2023.

Results: The review highlights several biologic therapies, including TNF-α inhibitors (e.g., adalimumab, etanercept) and IL-17 inhibitors (e.g., secukinumab, ixekizumab), which have demonstrated significant efficacy in reducing psoriasis symptoms and improving patient quality of life. Emerging therapies targeting IL-23, such as guselkumab and tildrakizumab, show promise in providing sustained remission. The efficacy of these biologics is often accompanied by manageable safety profiles, although some patients experience adverse effects that necessitate careful monitoring.

Conclusion: Biologic therapies and monoclonal antibodies represent a significant advancement in the management of psoriasis, offering targeted treatment options that improve patient outcomes. Continued research is essential to explore the long-term effects of these therapies, address any emerging safety concerns, and assess their impact on comorbid conditions associated with psoriasis. Future directions include the development of novel agents that enhance therapeutic efficacy while minimizing side effects.